Response-guided treatment of cirrhotic chronic hepatitis B patients: Multicenter prospective study

Table 1 Demographic data and laboratory results of the three arms at baseline

	Arm A (n = 49)	Arm B (n = 31)	Arm C (n = 20)	Statistics	P value
Median age (yr)	45 (38-52)	40 (36-50)	43.5 (40.5-55)	F = 0.8400	0.4345
Male:Female	41:8	25:6	15:5	χ2 = 0.6979	0.7050
HBeAg-positive, n (%)	13 (26.53)	21 (67.74)a	14 (70)a	χ2 = 17.7676	0.0000
Median PLT (× 109/L)	109 (73-150)	109 (89-144)	98.25 (76.5-122)	χ2 = 2.4880	0.2882
Median PT (s)	13.40 (12.6-14.3)	12.75 (12-13.7)c	14.30 (13-15.5)	χ2 = 10.1270	0.0063
Median albumin (g/L)	44 (39-46.8)	43 (40-47.6)	43.5 (40.9-47.3)	F = 0.0400	0.9600
Median TB (μmol/L)	17.35 (14.5-23.35)	15.8 (13.1-20.1)	18.35 (15.9-23.6)	χ2 = 2.1780	0.3366
Median ALT (U/L)	55 (43.2-87.5)	51 (34.5-82)	64 (48.5-91.6)	F = 0.400	0.6730
Median AST (U/L)	55 (41.05-68.5)	49 (30-57)	54.15 (45.5-66.5)	F = 1.5100	0.2251
Median HBV DNA (log10 IU/mL)	5.86 (5.16, 6.58)c	6.06 (5.77, 6.39)c	6.7 (6.29, 7.17)	F = 5.0300	0.0084

^aP <0.05 vs Arm A;

^cP <0.05 vs Arm C. HBeAg: Hepatitis B e antigen; PLT: Platelet counts; PT: Prothrombin time; TB: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HBV: Hepatitis B virus.